高反应患者中高纯度人绝经期促性腺激素与重组促卵泡激素的随机评估者盲法试验
这项随机、开放标签、评估者盲法、平行组非劣效性试验纳入620例血清抗苗勒管激素(AMH)≥5 ng/mL的女性,比较高纯度人绝经期促性腺激素(HP-hMG)与重组促卵泡激素(rFSH)在GnRH拮抗剂ART周期中的效果。新鲜移植后持续妊娠率HP-hMG组为35.5%、rFSH组为30.7%,非劣效性成立;HP-hMG组卵巢过度刺激综合征和累积早期妊娠丢失率显著更低,累积活产率相似。
要点
- 高反应患者中HP-hMG持续妊娠率非劣效于rFSH。
- HP-hMG组OHSS发生率9.7%,显著低于rFSH组21.4%。
- 两组累积活产率相似,HP-hMG风险/获益更优。
核心结论
- 在高反应患者中,HP-hMG疗效与rFSH相当,且不良事件(包括妊娠丢失)更少,提示其风险/获益特征更优。
研究设计与样本
- 随机、开放标签、评估者盲法、平行组、非劣效性试验,纳入620例血清AMH≥5 ng/mL的女性。
主要发现
- 新鲜移植后每周期启动的持续妊娠率HP-hMG组35.5%,rFSH组30.7%(差值4.7%,95%CI -2.7%, 12.1%),非劣效性成立。
- OHSS发生率HP-hMG组9.7%,rFSH组21.4%(差值-11.7%,95%CI -17.3%, -6.1%)。
- 累积早期妊娠丢失率HP-hMG组14.5%,rFSH组25.5%(差值-11.0%,95%CI -18.8%, -3.14%)。
- 累积活产率HP-hMG组50.6%,rFSH组51.5%(差值-0.8%,95%CI -8.7%, 7.1%),尽管rFSH组多43次移植。
临床怎么用
- 对 predicted high responders(AMH≥5 ng/mL)行GnRH拮抗剂ART控制性卵巢刺激时,可考虑选用HP-hMG以降低OHSS和妊娠丢失风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in a population of patients predicted to be high responders. DESIGN: Randomized, open-label, assessor-blinded, parallel-group, noninferiority trial. SETTING: Fertility centers. PATIENT(S): A total of 620 women with serum antimüllerian hormone (AMH) ≥5 ng/mL. INTERVENTION(S): Controlled ovarian stimulation with HP-hMG or rFSH in a GnRH antagonist assisted reproductive technology (ART) cycle. Fresh transfer of a single blastocyst was performed unless ovarian response was excessive, in which all embryos were cryopreserved. Subjects could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOME MEASURE(S): Ongoing pregnancy rate (OPR) after fresh transfer (primary endpoint), as well as cumulative live birth, ovarian hyperstimulation syndrome (OHSS), and pregnancy loss rates. RESULTS: OPR/cycle start after fresh transfer was 35.5% with HP-hMG and 30.7% with rFSH (difference: 4.7%, 95% CI -2.7%, 12.1%); noninferiority was established. Compared to rFSH, HP-hMG was associated with significantly lower OHSS (21.4% vs. 9.7% respectively; difference: -11.7%, 95% CI -17.3%, -6.1%) and cumulative early pregnancy loss rates (25.5% vs. 14.5% respectively; difference: -11.0%, 95% CI -18.8%, -3.14%). Despite 43 more transfers in the rFSH group, cumulative live birth rates were similar with HP-hMG and rFSH at 50.6% and 51.5% respectively (difference: -0.8%, 95% CI -8.7%, 7.1%). CONCLUSION(S): In high responders, HP-hMG provided comparable efficacy to rFSH with fewer adverse events, including pregnancy loss, suggesting its optimized risk/benefit profile in this population. CLINICAL TRIAL REGISTRATION NUMBER: NCT02554279 (clinicaltrials.gov).
引用
- Witz CA, Daftary GS, Doody KJ, et al. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertil Steril. 2020. PMID: 32416978. doi:10.1016/j.fertnstert.2020.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。